## AsahiKASEI

## Fiscal 2018 <br> Financial Results

- supplementary financial summary -


## May 10, 2019

Asahi Kasei Corporation

## Contents

## 1. Consolidated results for fiscal year 2018

8 Summary of financial results
9 Statements of income
10 Balance sheets
11 Cash flows
12 Sales and operating income by segment
13-14 Sales and operating income increase/decrease by business category
15-21 Overview of results by business category

## 2. Forecast for fiscal year 2019

23 Revision of business categories
24 Consolidated operating performance forecast
25-26 Sales and operating income forecast by segment

## 3. Appendix

29 Primary investments by business category
30 Major investments
31 Overseas sales by business category
32-34 Reference materials for Homes
35-37 Reference materials for Health Care
38 Extraordinary income and loss
39-40 Quarterly sales and operating income by business category

## Outline of fiscal year 2018 results (i)

Results for fiscal 2018
$>$ Highest ever net sales and operating income.
$\checkmark$ Operating income and net income attributable to owners of the parent above the forecast announced in February, revised downward from the original forecast reflecting impact of deterioration of market prices and slowdown in demand in the Material segment in the latter half of Q3.
Certain market price recovery in the Material segment, and firm performance of the Homes segment and the Health Care segment in Q4.
$\checkmark$ Sales and operating income increased year-on-year, underpinned by the following improvements in operating profit.
Material: increased shipments of nonwovens such as Lamous microfiber suede and Bemliese continuous-filament cellulose nonwoven, and improved terms of trade in acrylonitrile and engineering plastics.
Homes: firm performance of rental management and condominium construction in real estate.
Health Care: increased shipments of defibrillators for professional use in Critical Care.
> Second highest net income attributable to owners of the parent, after FY 2017.
$\checkmark$ Absense of one-time positive effect of tax reform in the US posted in FY 2017, and decrease in gain on sales of investment securities.

## Outline of fiscal year 2018 results (ii)

> Major M\&As in FY 2018
$\checkmark$ Sage Automotive Interiors, Inc., a US-based manufacturer of automotive interior material
$\checkmark$ Senseair AB, a Swedish manufacturer of gas sensor modules
$\checkmark$ Erickson Framing Operations LLC, a US-based supplier of pre-fabricated building products

## Shareholder returns

Dividend of $¥ 34$ per share for FY 2018. Share buyback of $¥ 10$ billion. Total return ratio at $39 \%$.

## Outline of fiscal year 2019 forecast (i)

## Forecast for fiscal 2019

$>$ Beginning with FY 2019, business categories in the Material segment are reclassified from the former Fibers, Chemicals, and Electronics, into Basic Materials, Performance Products, and Specialty Solutions. Refer to p. 23 for details.
> Under the uncertainty of business circumstances with US-China trade friction-related risks and slowdown of the world economy, realizing contribution from investments conducted under the former medium-term management initiative "Cs for Tomorrow 2018," and aiming for sustainable growth capitalizing on Asahi Kasei's strength as "a portfolio of highprofitability, high value-added businesses."
$>$ Increased sales, year-on-year
$\checkmark$ Continued expansion of Separators and Critical Care, and full-year effect of consolidation of Sage Automotive Interiors, Inc.

## Outline of fiscal year 2019 forecast (ii)

$>$ Slightly decreased operating income, year-on-year.
$\checkmark$ Impact of deterioration in terms of trade for certain commodity products and maintenance shutdown of naphtha cracker, however, benefit from growth in high-value added businesses in Performance Products and Specialty Solutions, as well as Homes and Critical Care.

Material: growth in Li-ion battery separator and Sage-related businesses.
Homes: increased deliveries of order-built homes resulting from increased orders in the previous fiscal year, and firm performance of rental management and condominium construction in real estate.
Health Care: continued growth in Critical Care.
$>$ Flat net income attributable to owners of the parent, year-on-year.

## Shareholder returns

$\checkmark$ Dividend of $¥ 36$ per share for FY 2019 planned, targeting stable and continuous dividend increases.
$\checkmark$ Shareholder returns policy for the next three years from FY 2019 to FY 2021 will be introduced in the next medium-term management initiative to be announced on May 29, 2019.

## 1. Consolidated results for fiscal year 2018

## AsahiKASEI

## Sunnmary of financiat resutus

|  | FY 2017 | FY 2018 |  | FY 2018 vs. FY 2017 |  | Result vs. forecast in Feb. |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Result | Forecast in Feb. | Increase (decrease) | \% change | Increase (decrease) | \% change |
| Net sales | 2,042.2 | 2,170.4 | 2,171.0 | 128.2 | +6.3\% | (0.6) | -0.0\% |
| Operating income | 198.5 | 209.6 | 201.0 | 11.1 | +5.6\% | 8.6 | +4.3\% |
| Ordinary income | 212.5 | 220.0 | 209.0 | 7.4 | +3.5\% | 11.0 | +5.3\% |
| Net income attributable to owners of the parent | 170.2 | 147.5 | 145.0 | (22.7) | -13.4\% | 2.5 | +1.7\% |
| Naphtha price ( $¥ / \mathrm{kL}$, domestic) | 41,925 | 49,400 | 49,350 | 7,475 |  | 50 |  |
| ¥/US\$ exchange rate (market average) | 111 | 111 | 111 | 0 |  | 0 |  |
| $¥ / €$ exchange rate (market average) | 130 | 128 | 128 | (1) |  | 0 |  |
| Net income per share (EPS) (¥) | 121.93 | 105.66 |  |  |  |  |  |
| Dividends per share (¥) | 34 | 34 |  |  |  |  |  |
| Payout ratio | 27.9\% | 32.2\% |  |  |  |  |  |
| Net income per total assets (ROA) | 7.4\% | 6.0\% |  |  |  |  |  |
| Net income per shareholders' equity (ROE) | 14.0\% | 11.1\% |  |  |  |  |  |

## AsahiKASEI

## Statements of income

|  | FY 2017 |  | FY 2018 |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | \% of sales |  | \% of sales |
| Net sales | 2,042.2 | 100.0\% | 2,170.4 | 100.0\% |
| Cost of sales | 1,393.1 | 68.2\% | 1,481.9 | 68.3\% |
| Gross profit | 649.1 | 31.8\% | 688.5 | 31.7\% |
| Selling, general and administrative expenses | 450.6 | 22.1\% | 479.0 | 22.1\% |
| Operating income | 198.5 | 9.7\% | 209.6 | 9.7\% |
| Net non-operating income (expenses) of which, net financing income (expense) net equity in earnings (losses) of affiliates foreign exchange gains (loss) | 14.1 $\begin{array}{r} 4.0 \\ 13.1 \\ (3.0) \\ \hline \end{array}$ |  | $\begin{array}{r} 10.4 \\ \\ 4.7 \\ 12.1 \\ (2.7) \end{array}$ |  |
| Ordinary income | 212.5 | 10.4\% | 220.0 | 10.1\% |
| Net extraordinary income (loss) | 5.8 |  | (9.6) | , |
| Income before income taxes | 218.3 | 10.7\% | 210.4 | 9.7\% |
| Income taxes <br> Net income attributable to non-controlling interests | $\begin{array}{r} (46.1) \\ (1.9) \end{array}$ |  | $\begin{array}{r} \hline(60.6) \\ (2.3) \end{array}$ |  |
| Net income attributable to owners of the parent | 170.2 | 8.3\% | 147.5 | 6.8\% |


| Increase <br> (decrease) | $\%$ change |
| ---: | ---: |
| 128.2 | $+6.3 \%$ |
| 88.7 | $+6.4 \%$ |
| 39.4 | $+6.1 \%$ |
| 28.3 | $+6.3 \%$ |
| 11.1 | $+5.6 \%$ |
| $(3.7)$ |  |
|  |  |
| 0.7 |  |
| $(1.0)$ |  |
| 0.3 |  |
| 7.4 | $+3.5 \%$ |
| $(15.4)$ |  |
| $(7.9)$ | $-3.6 \%$ |
| $(14.4)$ |  |
| $(0.4)$ |  |
| $(22.7)$ | $-13.4 \%$ |

## Balance sheets

|  | At end of Mar. 2018 | At end of Mar. $2019{ }^{1}$ | Increase <br> (decrease) |  | At end of Mar. 2018 | At end of Mar. $2019^{1}$ | Increase <br> (decrease) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Current assets | 938.9 | 1,051.4 | 112.4 | Liabilities | 1,001.9 | 1,172.5 | 170.6 |
| Cash and deposits | 156.3 | 193.9 | 37.6 | Current liabilities | 589.1 | 681.9 | 92.7 |
| Notes and accounts receivable-trade | 341.4 | 350.7 | 9.3 | Noncurrent liabilities ${ }^{2}$ | 412.8 | 490.6 | 77.8 |
| Inventories | 359.7 | 427.3 | 67.7 | Net assets <br> Shareholders' equity | 1,305.2 | 1,402.7 | 97.5 |
| Other current assets ${ }^{2}$ | 81.5 | 79.4 | (2.1) |  | 1,160.8 | 1,256.7 | 95.9 |
| Noncurrent assets | 1,368.2 | 1,523.8 | 155.6 | Capital stock | 103.4 | 103.4 | - |
| Property, plant and equipment <br> Intangible assets <br> Investments and other assets ${ }^{2}$ | 562.0 | 621.4 | 59.3 | Capital surplus | 79.4 | 79.7 | 0.3 |
|  | 414.6 | 530.0 | 115.4 | Retained earnings | 981.9 | 1,077.6 | 95.7 |
|  | 391.5 | 372.5 | (19.1) | Treasury stock | (3.9) | (3.9) | (0.0) |
|  |  |  |  | Accumulated other comprehensive income | 126.6 | 124.7 | (1.8) |
|  |  |  |  | Non-controlling interests | 17.8 | 21.2 | 3.4 |
| Total assets ${ }^{2}$ | 2,307.2 | 2,575.2 | 268.0 | Total liabilities and net assets ${ }^{2}$ | 2,307.2 | 2,575.2 | 268.0 |


| Interest-bearing debt | 301.7 | 424.9 | 123.1 |
| :--- | ---: | ---: | ---: |
| D/E ratio | 0.23 | 0.31 | 0.07 |

${ }^{1}$ Among the total assets at the end of March 2019, ¥143.5 billion is attributed to the effect of the consolidation, including acquisition-related goodwill, of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time).
2 "Partial Amendments to Accounting Standard for Tax Effect Accounting" is applied from FY 2018. Accordingly, all deferred tax assets are shown under investments and other assets, and all deferred tax liabilities are shown under noncurrent liabilities. The figures at the end of March 2018 have been revised retroactively to reflect the amendments.

## AsahiKASEI

## Cash flows

( $¥$ billion)

|  |  | FY 2017 | FY 2018 |
| :--- | :--- | ---: | ---: |
| a. $\quad$ Net cash provided by (used in) operating activities | 249.9 | 212.1 |  |
| b. Net cash used in investing activities | $(110.3)$ | $(198.9)$ |  |
| c. Free cash flows [a+b] | 139.6 | 13.1 |  |
| d. $\quad$ Net cash provided by (used in) financing activities | $(134.4)$ | 17.4 |  |
| e. $\quad$ Effect of exchange rate change on cash and cash equivalents | $(0.9)$ | 0.5 |  |
| f. $\quad$ Net increase (decrease) in cash and cash equivalents [c+d+e] | 4.2 | 31.1 |  |


| g. | Cash and cash equivalents at beginning of period | 144.1 | 148.6 |
| :--- | :--- | ---: | ---: |
| h.Increase in cash and cash equivalents resulting from changes <br> in scope of consolidation | 0.3 | 0.8 |  |
| i. | Cash and cash equivalents at end of period [f+g+h] | 148.6 | 180.5 |

## AsahiKASEI

## Sales and operating income by segment ${ }^{1}$

( $¥$ billion)


[^0]
# Sales and operating income increase/decrease by business category ${ }^{1}$ (i) 

( $¥$ billion)

|  |  | FY 2017 | FY 2018 | NetIncrease Increase (decrease) | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Fibers ${ }^{2}$ | Sales |  | 135.9 | 171.0 | 35.1 | 6.4 | 2.0 | (0.2) | 26.7 | - |
|  | Operating income | 12.1 | 14.8 | 2.7 | 0.8 | - |  |  | (0.0) |
| Chemicals | Sales | 799.3 | 853.6 | 54.2 | 8.5 | 41.7 | 0.0 | 4.0 | - |
|  | Operating income | 100.1 | 107.0 | 6.9 | (0.3) |  |  | - | (34.5) |
| Electronics | Sales | 152.5 | 151.7 | (0.8) | 0.6 | (4.2) | (0.5) | 2.8 | - |
|  | Operating income | 9.7 | 7.8 | (1.9) | (0.5) |  |  | - | 2.8 |
| Homes | Sales | 588.3 | 604.7 | 16.4 | 6.3 | 1.8 | - | 8.4 | - |
|  | Operating income | 60.2 | 63.5 | 3.3 | 1.7 |  |  | - | (0.2) |
| Construction Materials | Sales | 52.7 | 55.1 | 2.3 | 2.0 | 0.3 | - | - | - |
|  | Operating income | 4.0 | 4.7 | 0.7 | 0.9 |  |  | - | (0.6) |

[^1]
## Sales and operating income increase/decrease by business category ${ }^{1}$ (ii)

(¥ billion)

|  |  | FY 2017 | FY 2018 |  | Increase (decrease) due to: |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Sales volume |  |  | Sales prices | of which, due to foreign exchange | Others | Operating costs and others |
| Health Care | Sales |  | 135.7 | 135.5 | (0.2) | 3.5 | (2.5) | 0.0 | (1.2) | - |
|  | Operating income | 19.7 | 18.4 | (1.2) | 3.0 | - |  |  | (1.7) |
| Critical Care | Sales | 160.5 | 180.7 | 20.1 | 14.8 | 0.9 | (0.7) | 4.5 | - |
|  | Operating income | 19.8 | 23.4 | 3.6 | 6.8 |  |  | - | (4.1) |
| Others | Sales | 17.3 | 18.3 | 1.0 | 1.0 | - | - | - | - |
|  | Operating income | 1.9 | 2.4 | 0.5 | 0.9 |  |  | - | (0.4) |
| Corporate expenses and eliminations | Operating income | (29.0) | (32.4) | (3.4) | - | - | - | - | (3.4) |
| Consolidated | Sales | 2,042.2 | 2,170.4 | 128.2 | 43.1 | 40.0 | (1.4) | 45.1 | - |
|  | Operating income | 198.5 | 209.6 | 11.1 | 15.2 |  |  | - | (44.1) |

${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.

## Fibers ${ }^{1}$



[^2]${ }^{2}$ Increase (decrease) in sales prices excluding impact of foreign exchange.
${ }^{3}$ Impact of foreign exchange on sales prices.

## Review of operations

Impact of higher feedstock costs. Increased shipments of Lamous microfiber suede, Bemliese continuous-filament cellulose nonwoven, and other products. Improved terms of trade for Bemberg cupro fiber. Effect of consolidation of Sage Automotive Interiors, Inc. Sales and operating income increase.

## Highlights

- July, decision to acquire Sage Automotive Interiors, Inc., a US-based manufacturer of automotive interior material; consolidated in September.
- March, decision to increase production capacity for spunbond nonwovens in Thailand.


## Chemicals



## AsahiKASEI

## Electronics



## Review of operations

Separators:
Increased shipments of Li-ion battery separator. Decreased shipments of lead-acid battery separator due to global slowdown in automotive market. Sales increase, but operating income decrease.
Electronic devices:
Decreased sales of camera-module devices for smartphones. Sales and operating income decrease.

## Highlights

- April 2018, consolidation of Senseair AB, a Swedish manufacturer of gas-sensor modules.
- March 2019, announcement to enhance manufacturing infrastructure for LIB separator.


## Homes

\begin{tabular}{|c|c|c|c|c|c|c|}
\hline \multicolumn{7}{|r|}{( $¥$ billion)} <br>
\hline Sales \& \multicolumn{2}{|l|}{} \& \multicolumn{4}{|r|}{Operating income} <br>
\hline \multirow{2}{*}{600.0} \& 588.3 \& \multicolumn{2}{|l|}{\multirow[b]{2}{*}{$$
\begin{array}{r}
+16.4 \\
+2.8 \%
\end{array}
$$}} \& 604.7 \& \multicolumn{2}{|r|}{\multirow{2}{*}{80.0}} <br>
\hline \& \& \& \& \& \& <br>
\hline \multirow[t]{2}{*}{300.0

0.0} \& 60.2 \& \multicolumn{2}{|l|}{$$
\begin{gathered}
+3.3 \\
+5.5 \%
\end{gathered}
$$} \& 63.5 \& \multicolumn{2}{|r|}{40.0} <br>

\hline \& \& \& \& \& \multicolumn{2}{|r|}{0.0} <br>
\hline \multicolumn{7}{|c|}{FY 2017 FY 2018} <br>
\hline \multicolumn{7}{|r|}{(\# billion)} <br>
\hline \multirow[t]{2}{*}{} \& \multicolumn{2}{|r|}{FY 2017} \& \multicolumn{2}{|r|}{FY 2018} \& \multicolumn{2}{|l|}{Increase (decrease)} <br>
\hline \& Sales \& Operating income \& Sales \& Operating income \& Sales \& Operating income <br>
\hline Order-built homes, etc. (Asahi Kasei Homes) \& 406.8 \& 41.1 \& 403.7 \& 41.4 \& (3.1) \& 0.3 <br>

\hline | Real estate |
| :--- |
| (Asahi Kasei Realty \& Residence) | \& 124.1 \& 11.1 \& 135.4 \& 13.8 \& 11.4 \& 2.7 <br>


\hline | Remodeling |
| :--- |
| (Asahi Kasei Reform) | \& 55.2 \& 5.8 \& 58.4 \& 6.2 \& 3.2 \& 0.4 <br>

\hline Other housing-related, etc. \& 2.2 \& 2.3 \& 7.1 \& 2.1 \& 5.0 \& (0.2) <br>
\hline Total \& 588.3 \& 60.2 \& 604.7 \& 63.5 \& 16.4 \& 3.3 <br>
\hline
\end{tabular}

## Review of operations

Order-built homes:

- Decreased deliveries of Hebel Haus unit homes. Reduction of costs. Sales decrease, and operating income flat.
- Year-on-year $11.3 \%$ increase in value of new orders. Firm orders for unit homes. Some rush demand for multi-dwelling homes ahead of the consumption tax hike.
Real estate, remodeling and others:
Firm performance of both rental management and condominium construction in real estate. Sales and operating income increase.


## Highlights

- November, addition of brick vermilion to Hebel Haus exterior wall color variation.
- November, decision to acquire Erickson Framing Operations LLC, a US-based supplier of prefabricated building products; consolidated in December.
- April 2019, launch of housing with home-care services provided for the elderly in need of care.


## Construction Materials



## Health Care

Sales

## Review of operations

Pharmaceuticals:
Increased shipments of newer drugs such as Teribone osteoporosis drug, and Kevzara agent for rheumatoid arthritis. Decreased sales of long-listed drugs due to impact of reduced reimbursement prices and competition from generics. Sales and operating income decrease.
Devices:
Increased shipments of Planova virus removal filters. Impact of reduced reimbursement prices for dialysisrelated products. Sales increase, but operating income decrease.

## Highlights

- July, entry into distribution agreement with Stanbio Laboratory for the marketing of Lucica Glycated Albumin-L in the US.
- August, announcement of preliminary results of overseas Phase III clinical study for ART-123 (recombinant thrombomodulin alfa) for the treatment of severe sepsis with coagulopathy.
- October, application for approval to manufacture and sell Teribone autoinjector in Japan.
- December, launch of Kevzara autoinjector for treatment of rheumatoid arthritis in Japan.
- February, launch of Ribotest Legionella, extracorporeal diagnostic kits in Japan.
- February, obtaining partial change of approval for famciclovir for the treatment of recurrent herpes simplex.


## AsahiKASEI

## Critical Care



## Review of operations

Increased shipments of defibrillators for professional use. Sales and operating income increase.

Financial performance of Critical Care business category
(\$ million)

|  | H1 | H2 | FY 2017 | H1 | H2 | FY 2018 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 686 | 762 | 1,448 | 780 | 848 | 1,629 |
| Gross operating income before PPA ${ }^{1}$ impact | 138 | 162 | 300 | 163 | 170 | 333 |
| Amortization/depreciation from $\mathrm{PPA}^{1}$ revaluation | (61) | (61) | (122) | (60) | (62) | (122) |
| Goodwill <br> Other intangible assets, etc. | $\begin{aligned} & \hline(38) \\ & (23) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline(38) \\ & (23) \\ & \hline \end{aligned}$ | $\begin{aligned} & \hline(75) \\ & (47) \\ & \hline \end{aligned}$ | $\begin{aligned} & (37) \\ & (23) \\ & \hline \end{aligned}$ | $\begin{aligned} & (38) \\ & (24) \end{aligned}$ | $\begin{aligned} & (75) \\ & (47) \\ & \hline \end{aligned}$ |
| Consolidated operating income | 77 | 102 | 179 | 103 | 108 | 211 |

## AsahiKASEI

## 2. Forecast for fiscal year 2019

## AsahiKASEI

## Revision of business categories

Beginning with FY 2019, the business categories in the Material segment are reclassified from the former Fibers, Chemicals, and Electronics into Basic Materials, Performance Products, and Specialty Solutions.

| Segments | Business categories |  |  |
| :---: | :---: | :---: | :---: |
|  | Former |  | New |
| Material | Fibers |  | Basic Materials <br> (Former petrochemicals) |
|  | Chemicals <br> (Petrochemicals, performance polymers, performance materials and consumables) |  | Performance Products <br> (Former Fibers, performance polymers, consumables) |
|  |  |  | Specialty Solutions |
|  | Electronics <br> (Separators, electronic devices) |  | Others |
| Homes | No change |  |  |
| Health Care |  |  |  |  |
| Others |  |  |  |  |
| Corporate expenses and eliminations |  |  |  |  |

For purposes of comparison with FY 2019 forecasts, FY 2018 results are hereinafter recalculated in accordance with the new classifications.

## AsahiKASEI

## Consolidated operating performance forecast

(¥ billion)

|  | FY 2017 | FY 2018 |  | Total <br> a | FY 2019 |  | Total <br> b | Increase (decrease) b-a |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | H1 | H2 |  | H1 | H2 |  |  |
| Net sales | 2,042.2 | 1,041.5 | 1,128.9 | 2,170.4 | 1,088.0 | 1,180.0 | 2,268.0 | 97.6 |
| Operating income | 198.5 | 104.3 | 105.3 | 209.6 | 97.5 | 107.5 | 205.0 | (4.6) |
| Ordinary income | 212.5 | 110.3 | 109.7 | 220.0 | 102.0 | 112.0 | 214.0 | (6.0) |
| Net income attributable to owners of the parent | 170.2 | 78.9 | 68.6 | 147.5 | 67.0 | 80.5 | 147.5 | - |


| Naphtha price ( $¥ / k L$, domestic) | 41,925 | 51,100 | 47,700 | 49,400 | 47,000 | 47,000 | 47,000 | $(2,400)$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $¥ / \mathrm{US} \$$ exchange rate (market average) | 111 | 110 | 112 | 111 | 110 | 110 | 110 | (1) |
| $¥ / €$ exchange rate (market average) | 130 | 130 | 127 | 128 | 125 | 125 | 125 | (3) |
| Net income per share (EPS) ( $¥$ ) | 121.93 |  |  | 105.66 |  |  | 105.66 |  |
| Dividends per share ( $¥$ ) | 34 |  |  | 34 |  |  | $\begin{gathered} 36 \\ \text { (planned) } \end{gathered}$ |  |
| Payout ratio | 27.9\% |  |  | 32.2\% |  |  | 34.1\% |  |

## AsahiKASEI

## Sales forecast by business category

( $¥$ billion)

|  | FY 2018 (recalculated) |  |  | FY 2019 forecast |  |  | Increase <br> (decrease) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | H1 | H2 | Total | H1 | H2 | Total |  |
| Basic Materials | 205.5 | 194.2 | 399.7 | 173.0 | 178.0 | 351.0 | (48.7) |
| Performance Products ${ }^{1}$ | 214.2 | 242.9 | 457.1 | 245.0 | 254.0 | 499.0 | 41.9 |
| Specialty Solutions | 158.2 | 162.7 | 320.8 | 169.0 | 179.0 | 348.0 | 27.2 |
| Others | 0.2 | (1.7) | (1.5) | 1.0 | (2.0) | (1.0) | 0.5 |
| Material segment | 578.1 | 598.1 | 1,176.2 | 588.0 | 609.0 | 1,197.0 | 20.8 |
| Homes | 271.8 | 332.9 | 604.7 | 302.0 | 368.0 | 670.0 | 65.3 |
| Construction Materials | 26.9 | 28.2 | 55.1 | 28.0 | 29.0 | 57.0 | 1.9 |
| Homes segment | 298.7 | 361.1 | 659.8 | 330.0 | 397.0 | 727.0 | 67.2 |
| Health Care | 68.4 | 67.1 | 135.5 | 70.0 | 68.0 | 138.0 | 2.5 |
| Critical Care | 86.0 | 94.6 | 180.7 | 92.0 | 97.0 | 189.0 | 8.3 |
| Health Care segment | 154.5 | 161.7 | 316.2 | 162.0 | 165.0 | 327.0 | 10.8 |
| Others | 10.2 | 8.1 | 18.3 | 8.0 | 9.0 | 17.0 | (1.3) |
| Consolidated | 1,041.5 | 1,128.9 | 2,170.4 | 1,088.0 | 1,180.0 | 2,268.0 | 97.6 |

[^3]
## AsahiKASEI

## Operating income forecast by business category ${ }^{1}$

[^4]
## - Disclaimer -

The forecasts and estimates shown in this document are dependent on a variety of assumptions and economic conditions. Plans and figures depicting the future do not imply a guarantee of actual outcomes.

## AsahiKASEI

3. Appendix

## Primary investments by business category

( $¥$ billion)

$\begin{array}{llll}\text { Amortization of goodwill } 18.0 & 19.5\end{array}$

[^5]
## Major investments

## Completed in FY 2018

- Hipore Li-ion battery separator*

60 million $\mathrm{m}^{2} / \mathrm{y}$ capacity increase in Moriyama-shi, Shiga, Japan, H1 FY 2018.

- Solution-polymerized styrene-butadiene rubber (S-SBR)*

30,000 t/y capacity increase in Singapore, Jan. 2019.

## Under construction at FY 2018 year-end

- Hipore Li-ion battery separator* 200 million $\mathrm{m}^{2}$ /y capacity increase in Moriyama-shi, Shiga, Japan, H1 FY 2019.
- Lamous microfiber suede*

3 million $\mathrm{m}^{2} / \mathrm{y}$ capacity increase in Nobeoka-shi, Miyazaki, Japan, H1 FY 2019.

- Li-ion battery separator*

Celgard - 150 million $\mathrm{m}^{2} / \mathrm{y}$ capacity increase in North Carolina, the US, H2 2018; Hipore - 90 million $\mathrm{m}^{2} / \mathrm{y}$ capacity increase in Moriyama-shi, Shiga, Japan, H1 FY 2020.

- Leona nylon 66 filament

5,000 t/y capacity expansion in Nobeoka-shi, Miyazaki, Japan, H1 FY 2019.

- Planova virus removal filters*
$40,000 \mathrm{~m}^{2} / \mathrm{y}$ capacity expansion for cellulose hollow-fiber in Nobeoka-shi, Miyazaki, Japan, May 2019.

[^6]
## Overseas sales by business category

( $¥$ billion)

|  | FY 2017 |  |  | FY 2018 |  |  | Increase (decrease) | \% change |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Total sales | Overseas sales | \% of total | Total sales | Overseas sales | \% of total |  |  |
| Fibers ${ }^{1}$ | 135.9 | 62.3 | 45.8\% | 171.0 | 94.0 | 55.0\% | 31.7 | +50.8\% |
| Chemicals | 799.3 | 395.2 | 49.4\% | 853.6 | 429.0 | 50.3\% | 33.8 | +8.6\% |
| Electronics | 152.5 | 105.5 | 69.2\% | 151.7 | 106.7 | 70.3\% | 1.2 | +1.1\% |
| Homes | 588.3 | - | - | 604.7 | 4.5 | 0.7\% | 4.5 | - |
| Construction Materials | 52.7 | 0.1 | 0.1\% | 55.1 | 0.1 | 0.2\% | 0.0 | +68.9\% |
| Health Care | 135.7 | 42.8 | 31.5\% | 135.5 | 44.8 | 33.1\% | 2.0 | +4.7\% |
| Critical Care | 160.5 | 158.3 | 98.6\% | 180.7 | 178.5 | 98.8\% | 20.2 | +12.7\% |
| Others | 17.3 | 3.5 | 20.3\% | 18.3 | 1.7 | 9.2\% | (1.8) | -52.1\% |
| Total | 2,042.2 | 767.7 | 37.6\% | 2,170.4 | 859.3 | 39.6\% | 91.6 | +11.9\% |
| Asia of which, sales to China |  | $\begin{aligned} & 443.5 \\ & 183.4 \end{aligned}$ | $\begin{array}{r} 21.7 \% \\ 9.0 \% \end{array}$ |  | $\begin{aligned} & 483.2 \\ & 211.5 \end{aligned}$ | $\begin{array}{r} 22.3 \% \\ 9.7 \% \end{array}$ | $\begin{aligned} & 39.7 \\ & 28.1 \end{aligned}$ | $\begin{array}{r} +9.0 \% \\ +15.3 \% \end{array}$ |
| The Americas |  | 209.6 | 10.3\% |  | 249.9 | 11.5\% | 40.3 | +19.2\% |
| Europe |  | 94.9 | 4.6\% |  | 104.5 | 4.8\% | 9.6 | +10.1\% |
| Other countries | $\sqrt{ }$ | 19.6 | 1.0\% |  | 21.6 | 1.0\% | 2.0 | +10.1\% |


| Sales, excluding Homes <br> and Construction Materials | $1,401.2$ | 767.6 | $54.8 \%$ | $1,510.6$ | 854.6 | $56.6 \%$ |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |

${ }^{1}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

## Homes: Sales and order trends

|  |  | Value of new orders during the term |  | Sales of order-built homes, etc. ${ }^{1}$ |  | Sales of real estate ${ }^{1}$ |  |  |  | Sales of remodeling | Other sales | Consolidated |  | Order <br> backlog |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Pre-built homes | Rental housing |  |  | Other | Total |  |  |  |  |  |
| FY15 | H1 |  |  | 217.3 | (-0.2\%) | 183.8 | (-2.2\%) | 10.4 | 33.5 | 1.7 | 45.6 | 27.8 | 0.9 | 258.0 | (+0.8\%) | 554.6 |
|  | H2 | 183.1 | (-12.0\%) | 227.7 | (+5.3\%) | 27.7 | 39.0 | 1.8 | 68.4 | 28.1 | 0.7 | 325.0 | (+9.9\%) | 513.1 |
|  | annual | 400.4 | (-5.9\%) | 411.5 | (+1.8\%) | 38.1 | 72.5 | 3.5 | 114.1 | 55.9 | 1.6 | 583.0 | (+5.7\%) |  |
| FY16 | H1 | 206.6 | (-4.9\%) | 183.5 | (-0.1\%) | 11.8 | 41.2 | 1.8 | 54.8 | 27.0 | (0.5) | 264.8 | (+2.6\%) | 538.8 |
|  | H2 | 194.3 | (+6.1\%) | 220.8 | (-3.1\%) | 9.5 | 43.5 | 1.6 | 54.6 | 29.1 | 0.8 | 305.3 | (-6.1\%) | 515.8 |
|  | annual | 400.9 | (+0.1\%) | 404.3 | (-1.8\%) | 21.3 | 84.7 | 3.4 | 109.4 | 56.1 | 0.4 | 570.2 | (-2.2\%) | - |
| FY17 | H1 | 193.1 | (-6.5\%) | 182.7 | (-0.4\%) | 12.0 | 45.3 | 1.6 | 59.0 | 26.8 | 1.1 | 269.6 | (+1.8\%) | 528.9 |
|  | H2 | 212.5 | (+9.4\%) | 224.1 | (+1.5\%) | 14.7 | 47.8 | 2.5 | 65.1 | 28.4 | 1.1 | 318.7 | (+4.4\%) | 520.9 |
|  | annual | 405.6 | (+1.2\%) | 406.8 | (+0.6\%) | 26.8 | 93.2 | 4.2 | 124.1 | 55.2 | 2.2 | 588.3 | (+3.2\%) | - |
| FY18 | H1 | 210.1 | (+8.8\%) | 175.5 | (-4.0\%) | 16.8 | 49.7 | 1.6 | 68.1 | 27.2 | 1.0 | 271.8 | (+0.8\%) | 557.8 |
|  | H2 | 241.5 | (+13.6\%) | 228.2 | (+1.8\%) | 13.2 | 52.1 | 2.1 | 67.4 | 31.2 | 6.1 | 332.9 | (+4.5\%) | 575.0 |
|  | annual | 451.6 | (+11.3\%) | 403.7 | (-0.8\%) | 29.9 | 101.8 | 3.7 | 135.4 | 58.4 | 7.1 | 604.7 | (+2.8\%) |  |
| FY19 | annual | 451.6 | ( - ) | 431.0 | (+6.8\%) | 37.0 | 110.5 | 6.5 | 154.0 | 63.5 | 21.5 | 670.0 | (+10.8\%) | 613.6 |

${ }^{1}$ As the rental management operation of Asahi Kasei Homes was transferred to Asahi Kasei Realty \& Residence, the corresponding sales previously included in order-built homes, etc., are combined with rental housing under real estate beginning with H2 2015.

## AsahiKASEI

## Homes: Breakdown of sales and orders (i)

## FY 2018 sales and orders of Asahi Kasei Homes

(\% change from previous year)

|  |  | Net sales |  | Number of units sold |  | Orders received |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | ( $¥$ billion) | (\% change) | (units) | (\% change) | ( $¥$ billion) | (\% change) | (units) | (\% change) |
| Unit homes | 1-2 story | 216.6 | $-2.3 \%$ | 6,721 | -3.2\% | 229.0 | +8.5\% | 6,852 | +4.1\% |
|  | $3+$ story | 82.7 | -0.6\% | 3,127 | -0.1\% | 90.0 | +3.7\% | 3,134 | $-2.4 \%$ |
|  | Total | 299.3 | $-1.9 \%$ | 9,848 | $-2.3 \%$ | 319.0 | +7.1\% | 9,986 | +2.0\% |
| Multidwelling homes | 1-2 story | 33.4 | +9.0\% | 2,292 | +7.3\% | 40.1 | +19.5\% | 2,792 | +18.9\% |
|  | $3+$ story | 64.8 | -0.3\% | 4,440 | -0.1\% | 92.4 | +24.7\% | 5,788 | +17.5\% |
|  | Total | 98.1 | +2.7\% | 6,732 | +2.3\% | 132.6 | +23.0\% | 8,580 | +17.9\% |
| Order-built homes total |  | 397.4 | -0.8\% | 16,580 | -0.5\% | 451.6 | +11.3\% | 18,566 | +8.8\% |
| Other ${ }^{1}$ |  | 6.3 | -0.7\% | 10 | -33.3\% | - | - | - | - |
| Asahi Kasei Homes total |  | 403.7 | -0.8\% | 16,590 | -0.5\% | 451.6 | +11.3\% | 18,566 | +8.8\% |

[^7]
## AsahiKASEI

## Homes: Breakdown of sales and orders (ii)

FY 2019 sales and order forecast of Asahi Kasei Homes
(\% change from previous year)

${ }^{1}$ Includes certain parcel sales and maintenance, etc.

## AsahiKASEI

## Health Care: Breakdown of sales

Sales of Health Care business category
( $¥$ billion)

|  | FY 2017 |  |  | FY 2018 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | H1 | H2 | Total | H1 | H2 | Total |
| Domestic pharmaceuticals | 30.5 | 29.6 | 60.1 | 29.4 | 29.0 | 58.3 |
| Others | 2.8 | 2.9 | 5.7 | 2.8 | 3.4 | 6.1 |
| Asahi Kasei Pharma consolidated | 33.3 | 32.5 | 65.8 | 32.2 | 32.3 | 64.5 |
| Devices ${ }^{1}$ | 33.0 | 36.9 | 70.0 | 36.3 | 34.8 | 71.0 |
| Total | 66.3 | 69.4 | 135.7 | 68.4 | 67.1 | 135.5 |

${ }^{1}$ Asahi Kasei Medical and its affiliate companies.
Main pharmaceuticals domestic sales
( $¥$ billion)

|  | FY 2017 |  |  | FY 2018 |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
|  | H1 | H2 | Total | H1 | H2 | Total |
| Teribone | 13.3 | 13.5 | 26.8 | 14.4 | 13.9 | 28.3 |
| Recomodulin | 5.8 | 6.1 | 11.8 | 6.0 | 5.8 | 11.8 |
| Flivas | 2.5 | 2.1 | 4.6 | 1.8 | 1.5 | 3.3 |
| Bredinin | 1.9 | 1.7 | 3.6 | 1.6 | 1.4 | 3.0 |
| Elcitonin | 1.9 | 1.5 | 3.4 | 1.2 | 1.1 | 2.3 |
| Reclast | 0.5 | 0.6 | 1.1 | 0.7 | 0.7 | 1.4 |
| Kevzara | - | 0.0 | 0.0 | 0.3 | 1.0 | 1.3 |

## Health Care: Main pharmaceutical products

|  | Generic name | Classifications | Indication | Formulation |
| :--- | :--- | :--- | :--- | :--- |
| Teribone | Teriparatide <br> acetate | Synthetic human <br> parathyroid <br> hormone (PTH) | Osteoporosis with high <br> risk of fracture | Injection |
| Reclast | Zoledronic acid | Osteoporosis drug | Osteoporosis | Injection |
| Recomodulin | Recombinant <br> thrombomodulin <br> alfa | Anticoagulant | Disseminated <br> intravascular <br> coagulation | Injection |
| Kevzara | Sarilumab <br> (rDNA origin) | Interleukin-6 <br> inhibitor | Rheumatoid arthritis not <br> responding well to <br> conventional treatments | Injection |
| Flivas | Naftopidil | Dysuria treatment | Benign prostatic <br> hyperplasia | Tablet |
| Elcitonin | Elcatonin | Eel calcitonin <br> derivative | Osteoporosis pain | Injection |
| Bredinin | Mizoribine | Immunosuppressant | Rheumatoid arthritis, <br> kidney transplantation, <br> nephrotic syndrome, <br> lupus nephritis | Tablet |

## Health Care: Pharmaceutical pipeline

| Development <br> stage | Code name, form, <br> generic name | Classifications | Indication | Region | Origin | Remarks |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- |
| Pending <br> approval | MN-10-T, <br> autoinjection, <br> teriparatide acetate | Osteoporosis drug | Osteoporosis with <br> high risk of fracture | Japan | In-house | New <br> formulation; <br> new dose |
| Phase III | AK1820, injection/ <br> capsule, <br> isavuconazole | Antifungal agent | Invasive fungal <br> infections | Japan | Licensed |  |
| Phase II | ART-123, injection, <br> recombinant <br> thrombomodulin <br> alfa | Anticoagulant | Chemotherapy- <br> induced peripheral <br> neuropathy (CIPN) | Japan | In-house | Additional <br> indication |
| Pending <br> approval <br> (overseas) | Flivas, tablet, <br> naftopidil | Dysuria treatment | Benign prostatic <br> hyperplasia | China | In-house |  |
|  | ART-123, injection, <br> recombinant <br> thrombomodulin <br> alfa | Anticoagulant | Severe sepsis with <br> coagulopathy | United <br> States, <br> Europe, <br> etc. | In-house |  |
| Phase III <br> (overseas) | HE-69, tablet, <br> mizoribine | Immunosuppressant | Lupus nephritis, <br> nephrotic syndrome | China | In-house | Additional <br> indication |

## AsahiKASEI

## Extraordinary income and loss

|  |  | FY 2017 | FY 2018 | Increase <br> (decrease) |
| :--- | :--- | ---: | ---: | ---: |
| Gain on sales of investment securities <br> Total extraordinary income |  | 15.2 | 11.6 | $(3.6)$ |
| Gain on sales of noncurrent assets | 0.5 | 0.7 | 0.1 |  |
| Loss on valuation of investment securities | 15.7 | 12.2 | $(3.5)$ |  |
| Loss on disposal of noncurrent assets | 0.0 | 0.2 | 0.1 |  |
| Impairment losses | 6.3 | 6.6 | 0.4 |  |
| Business structure improvement expenses | 2.2 | 11.1 | 8.9 |  |

## Quarterly sales by business category

(¥ billion)

|  | FY 2017 |  |  |  |  | FY 2018 |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | :---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |  |
| Fibers $^{1}$ | 32.0 | 34.1 | 34.7 | 35.1 | 36.2 | 36.7 | 49.6 | 48.5 |  |
| Chemicals $^{\text {}}$ | 178.3 | 196.8 | 214.1 | 210.1 | 205.6 | 221.7 | 221.5 | 204.7 |  |
| Electronics | 36.5 | 41.2 | 39.8 | 35.0 | 38.4 | 39.5 | 40.2 | 33.6 |  |
| Homes | 115.6 | 154.0 | 134.7 | 183.9 | 115.7 | 156.1 | 132.8 | 200.1 |  |
| Construction Materials | 12.6 | 13.5 | 14.5 | 12.1 | 13.0 | 13.9 | 15.4 | 12.8 |  |
| Health Care | 32.7 | 33.6 | 36.7 | 32.7 | 34.7 | 33.8 | 35.6 | 31.5 |  |
| Critical Care | 37.3 | 38.8 | 40.8 | 43.5 | 41.7 | 44.4 | 45.9 | 48.7 |  |
| Others | 3.6 | 4.0 | 4.4 | 5.2 | 4.6 | 5.6 | 4.4 | 3.7 |  |
| Total | 448.7 | 516.0 | 519.8 | 557.7 | 489.8 | 551.7 | 545.3 | 583.7 |  |

${ }^{1}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

# Quarterly operating income by business category ${ }^{1}$ 

|  | FY 2017 |  |  |  | FY 2018 |  |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
|  | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 |
|  | 3.5 | 3.1 | 3.0 | 2.6 | 3.9 | 3.4 | 3.8 | 3.8 |
|  | 22.5 | 26.0 | 30.1 | 21.4 | 28.6 | 30.7 | 27.2 | 20.5 |
|  | 2.0 | 3.6 | 3.7 | 0.4 | 2.5 | 3.1 | 3.3 | $(1.1)$ |
|  | 6.9 | 17.3 | 11.9 | 24.0 | 7.1 | 17.2 | 11.1 | 28.1 |
|  | 0.7 | 1.1 | 1.7 | 0.5 | 0.8 | 1.1 | 1.9 | 0.9 |
|  | 5.3 | 4.6 | 8.2 | 1.6 | 7.2 | 3.5 | 6.5 | 1.2 |
|  | 3.7 | 4.8 | 5.4 | 5.9 | 5.1 | 6.3 | 5.6 | 6.5 |
| Others | 0.0 | 0.6 | 0.4 | 0.8 | 0.6 | 0.6 | 0.4 | 0.8 |
| Corporate expenses <br> and eliminations | $(6.9)$ | $(6.4)$ | $(7.9)$ | $(7.9)$ | $(7.8)$ | $(9.4)$ | $(7.4)$ | $(7.8)$ |
| Total | 37.9 | 54.8 | 56.5 | 49.3 | 47.9 | 56.4 | 52.4 | 52.9 |

[^8]
## Creating for Tomorrow

The commitment of the Asahi Kasei Group:
To do all that we can in every era to help the people of the world make the most of life and attain fulfillment in living.

Since our founding, we have always been deeply committed
to contributing to the development of society,
boldly anticipating the emergence of new needs.
This is what we mean by "Creating for Tomorrow."

## AsahiKASEI


[^0]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

[^1]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

[^2]:    ${ }^{1}$ Including results of Sage Automotive Interiors, Inc. etc. from Q3 2018.

[^3]:    ${ }^{1}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Performance Products business category from Q3 2018.

[^4]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Performance Products business category from Q3 2018.

[^5]:    ${ }^{1}$ Amortization of goodwill is excluded and shown separately below the table.
    ${ }^{2}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

[^6]:    * Investment of $¥ 3$ billion or more.

[^7]:    ${ }^{1}$ Includes certain parcel sales and insurance commissions, etc.

[^8]:    ${ }^{1}$ Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals.
    ${ }^{2}$ Results of Sage Automotive Interiors, Inc. and its consolidated subsidiaries, acquired on September 27, 2018 (US Eastern time), are included in the Fibers business category from Q3 2018.

